ADAR1 Capital Management LLC Acquires New Position in Natera, Inc. $NTRA

Key Points

• ADAR1 Capital Management LLC has invested $601,000 in Natera, acquiring 4,250 shares of the medical research company.
• Institutional investors hold 99.90% of Natera's stock, with notable increases from Vanguard Group, Price T Rowe Associates, and others during the first quarter.
• Analysts have a consensus rating of "Buy" for Natera, with price targets ranging from $183.00 to $210.00 set by various research firms.

ADAR1 Capital Management LLC bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the first quarter, according to its most recent filing with the SEC. The firm bought 4,250 shares of the medical research company's stock, valued at approximately $601,000.

Other institutional investors also recently bought and sold shares of the company. LRI Investments LLC acquired a new stake in Natera in the 4th quarter worth approximately $29,000. Bank of Jackson Hole Trust acquired a new stake in Natera in the 1st quarter worth approximately $29,000. Rakuten Securities Inc. boosted its stake in Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after purchasing an additional 119 shares in the last quarter. TCTC Holdings LLC lifted its stake in Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock valued at $33,000 after acquiring an additional 124 shares during the period. Finally, ORG Partners LLC acquired a new stake in Natera during the 1st quarter valued at approximately $32,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider John Fesko sold 678 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $105,401.88. Following the completion of the sale, the insider owned 152,747 shares of the company's stock, valued at approximately $23,746,048.62. The trade was a 0.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rowan E. Chapman sold 2,750 shares of the business's stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the sale, the director directly owned 6,015 shares of the company's stock, valued at approximately $1,004,444.85. The trade was a 31.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 55,344 shares of company stock worth $8,271,610 in the last 90 days. 5.63% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have commented on the stock. Morgan Stanley restated an "overweight" rating and set a $195.00 price objective on shares of Natera in a research note on Sunday, August 10th. UBS Group lifted their price objective on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Piper Sandler restated an "overweight" rating and set a $220.00 price objective (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 price objective for the company in a research note on Monday, July 28th. Finally, Barclays restated an "overweight" rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $194.00.

Natera Stock Performance

Shares of Natera stock traded up $1.46 on Friday, hitting $168.02. The company's stock had a trading volume of 776,006 shares, compared to its average volume of 1,211,789. Natera, Inc. has a 1 year low of $110.57 and a 1 year high of $183.00. The firm has a fifty day moving average price of $154.35 and a 200-day moving average price of $153.91. The company has a market capitalization of $23.06 billion, a price-to-earnings ratio of -87.97 and a beta of 1.68.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analysts' expectations of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera's revenue was up 32.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. As a group, analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.